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Abstract The biological chemistry that underlies and regulates
the blood coagulation cascade is not fully understood. To begin to
understand this, we performed clotting assays under various
redox conditions. By varying the amount of oxidant and/or
antioxidant in these assays, we observed that both the intrinsic/
tenase complex and the extrinsic pathways were susceptible to
shifts in the thiol/redox balance. We established a dichotomy
where blood clotting via the intrinsic pathway was sensitive to
oxidation whereas the tissue factor or extrinsic pathway was
more sensitive to reduction. These differential inhibitory effects
present a conceptual mechanism for selective modulation of the
activities of clotting factors specific for the respective pathways.
These data also suggest that blood clotting may be influenced by
unidentified redox or thiol equilibria. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Reduction^oxidation or redox reactions are central not
only to intermediary metabolism, but also to the integration
and control of a diverse array of interactions including gene
regulation by transcription factors, protein^protein interac-
tions, and DNA synthesis [1]. Examples of proteins involved
in these processes include necrosis factor (NF)-UB, ribonu-
cleotide reductase, cytochrome c oxidase, and protein kinase
C. Most of these contain metal ion ligation sites (mainly cop-
per or iron) that constitute redox active sites. The body is also
equipped with proteins such as catalase and superoxide dis-
mutase which bu¡er against oxidant stress. Reactive oxygen
species (ROS) derived from phagocyte oxidative burst or UV
irradiation contribute to diseases as diverse as arthritis and
autoimmune diseases, for example, systemic lupus erythroma-
tosis. Phagocytes however also use ROS to protect the cell
against pathogen invasion. Thus, redox reactions seem to
span the entire spectrum of cell biology.
In blood, there are a number of redox proteins including a
major cellular antioxidant caeruloplasmin. Protein disulphide
isomerase, a potent redox cofactor involved in disulphide-
bond formation and isomerisation, has also been localised
on the platelet surface and mediates platelet aggregation [2^
4]. The latter can be inhibited by reduced glutathione [5]. It is
well established that redox reactions involving vitamin K
underlie the biology of clotting factors VII, IX, X, protein S
and prothrombin [6]. Vitamin K is required for post-transla-
tional carboxylation of these proteins by converting glutamate
to Q-carboxylglutamate residues. It is suggested that this pro-
cess may be coupled to disulphide-bond formation [7]. It
would appear that redox or thiol chemistry may have a role
in controlling e¡ector proteins of the coagulation system.
Here we examine the possible role of oxidants and antioxi-
dants in blood clotting in vitro, by inducing shifts in the thiol/
redox balance in the environment of the cognate clotting fac-
tors.
2. Materials and methods
2.1. Blood coagulation assays
Prothrombin times (PT) and activated partial thromboplastin times
(APTT) were determined using pooled normal plasma. For PT deter-
mination, rabbit brain thromboplastin, PT HS-Plus (Instrumentation
Laboratories Warrington, UK), was reconstituted in bu¡er as in-
structed. Normal plasma (75 Wl) was incubated with various concen-
trations of 5,5P-dithiobis(2-nitrobenzoic acid) (DTNB; Sigma), re-
duced glutathione (GSH; Calbiochem) or oxidised glutathione
(GSSG; Calbiochem). Normal saline was added where necessary to
bring the total reaction volume to 100 Wl. The mixture was incubated
for 15 min at 37‡C, and 100 Wl thromboplastin was added. APTT
were performed using micronised silica reconstituted in distilled water,
as activator. Normal plasma and DTNB, GSH or GSSG were incu-
bated as above; 100 Wl of activator and 100 Wl phospholipid were then
added. In a modi¢cation of the APTT assay, DTT was added to
various concentrations of GSSG at a ¢nal concentration of 5 mM.
Clot formation was initiated in all cases by adding 100 Wl 25 mM
CaCl2, and monitored on a KC-10 semi-automatic coagulometer
(Amelung). All assays were repeated four times.
3. Results and discussion
PT employs tissue thromboplastin to determine the integrity
and activity of the extrinsic clotting system based on the levels
of the vitamin K-dependent cofactors factors II, V, VII and
X. The APTT on the other hand is measured using a platelet
substitute (phospholipid) and an activator. It determines the
activity of the contact or intrinsic pathway and the levels of
factors VIII and IX, but may also indicate the activities of
high molecular weight kininogen, prekallikrein and factor XI.
Both the extrinsic and intrinsic pathways converge at factor X
to constitute the common pathway which leads to ¢brin clot
formation at the site of vascular injury. The underlying bio-
chemistry of these pathways is far from clear. We therefore
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initiated our study with one simple premise: that a regulatory
mechanism possibly involving covalent modi¢cations may be
involved in controlling both the qualitative and quantitative
response of the clotting factors to tissue injury. As a starting
point, we chose to study the e¡ects of modi¢cations of disul-
phide/sulphydryl groups of the proteins on the rate of blood
coagulation.
DTNB, otherwise known as Ellman’s reagent, is a potent
oxidant and thiol blocker that oxidises free thiols to disul-
phides. It is cell-impermeant and reacts with only exposed
thiols. We tested it to determine what e¡ect, if any, it had
on clotting factor activity and the time course of blood coag-
ulation. We observed that it prolonged ¢brin clot formation
via the intrinsic pathway (Fig. 1A) but had no inhibitory
e¡ect on the extrinsic or tissue factor pathways (Fig. 1B).
Because DTNB is not ordinarily present in systemic circula-
tion, we tested the physiological redox couple of GSH and
GSSG for their ability to modulate blood coagulation. Both
of these prolonged clotting time in a dose-dependent manner
(Fig. 2). The extrinsic pathway (measured by PT) appeared to
be sensitive both to oxidation and to reduction, since both
GSSG and GSH inhibited at high concentrations (Fig.
2A,B). Whereas no component of the intrinsic pathway
seemed very sensitive to reduction with GSH (Fig. 2C), it
appeared that some component in this pathway was sensitive
to oxidation since clotting was markedly inhibited by GSSG
(Fig. 2D). This mirrored the e¡ect of DTNB on the same
pathway, even at lower concentrations (Fig. 1A).
To relieve the inhibitory e¡ect of GSSG, we performed
Fig. 1. E¡ect of DTNB on blood clotting. APTT (A) and PT (B)
were determined using normal plasma as described in the text, with
various concentrations of DTNB. Horizontal bar represents the
upper limit for normal values. For APTT the range is 28^38 s,
while the normal range for PT is 12^16 s. Each value represents the
means þ S.E.M. of four independent experiments.
Fig. 2. GSH and GSSG have divergent e¡ects on blood clotting. PT
were determined as a function of GSH (A) or GSSG (B) concentra-
tions. APTT were similarly performed for GSH (C) and GSSG (D)
as described in the text. Horizontal bar represents upper range for
normality. Each value represents the means þ S.E.M. of four inde-
pendent experiments.
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APTT assays as above but also included DTT in the assay
mixture. We observed that DTT could partially reverse the
inhibitory e¡ect of GSSG at a GSSG:DTT ratio of 4:5
(Fig. 3). This reversal corresponds to the reduction of factor
VIII activity to between 20 and 25% of normal plasma levels.
On either side of this ratio, clotting times were dramatically
prolonged in a manner that re£ected the e¡ects of either of
these reagents on their own. Thus, it may be assumed that a
redox or thiol balance is required in order to override the
e¡ects of either inhibitor.
The comparatively marked prolongation of clotting time
that we observed in the APTT indicates that dithiol^disul-
phide interchange may have a more signi¢cant contribution
to the intrinsic than to the extrinsic pathway. The converse is
true for the PT. The inhibition of clotting by GSSG via both
the intrinsic and extrinsic pathways, albeit at high concentra-
tions, may also suggest that it acts on some component of the
common pathway, i.e. from factor Xa to ¢brin clot formation.
Thiol oxidation would appear to be the mechanism of inhibi-
tion. Previous reports have also shown that the reduction of
clotting factors by the thioredoxin system (comprising thiore-
doxin and thioredoxin reductase) and the alkylation of thiols
of these proteins completely abolished their activity [8]. Sim-
ilar studies, which are supported by our observations, sug-
gested that redox mechanisms may contribute to factor VIII
function and blood clotting [9]. Disulphide interchange has
also been observed to underlie the functions of ¢brinogen
[10] and thrombospondin [11]. Our ¢ndings also complement
other studies which showed that activated polymorphonuclear
leukocytes secreted potent oxidants, chloramine and hypo-
chlorous acid, which di¡erentially a¡ected the functions of
several clotting factors. While factors II (prothrombin), VII,
IX, XII and XIII were insensitive to oxidation, factors I (¢-
brinogen), V, VIII and X were inactivated by oxidation [12].
One possible explanation for our observations and those
preceding them is that the interaction of the clotting factors
may involve the formation of transient mixed-disulphide in-
termediates that require critical cysteine thiols. DTNB or glu-
tathione may block this process by competing for and seques-
tering those thiols and thus slowing down the process of
thrombin and ¢brin clot formation. On the other hand, since
(all) these proteins are disulphide-bonded de novo, a change
in the thiol or redox status of any one of them and the cor-
responding change in its activity, may be ampli¢ed down the
clotting cascade. Since clotting depends on a cascade of in-
tricately linked catalytic processes, a very small change in
activity of one component could lead to measurable changes
in clotting time. This may therefore indicate that the redox
state of the procoagulant complex or of the constituent e¡ec-
tor proteins, may determine its level of activity. This observa-
tion may have physiological signi¢cance that suggests that a
¢ne redox balance may be required in vivo for blood homeo-
stasis.
Glutathione is a major cellular constituent and acts as a
bu¡er against oxidant stress. It modulates the redox/thiol
state and function of a number of proteins including receptors
and metabolic enzymes. Although we have shown that blood
clotting is sensitive to the glutathione redox couple in vitro, it
may not in itself be involved physiologically since its concen-
tration in plasma is several orders of magnitude lower than
that used in the above assays [13]. However, the e¡ects that
we observed would suggest that an unidenti¢ed physiological
oxidant/antioxidant system may play a role in modulating
blood-clotting chemistry in vivo. The thioredoxin system or
a related one such as the glutataredoxin system must remain
potential regulatory mechanisms for the clotting factors as
indicated above, since thioredoxin can be detected in plasma
[1,8,14,15]. Taking our observations together with other re-
ports, we could speculate that thiol^disulphide interchange
[16] may be a rate-limiting step in the activities of the various
clotting factors and may also underpin the integration and
control of the clotting cascade.
What are the clinical implications of these observations? It
is known that the prolongation of clotting times by as little as
2 s can lead to a bleeding diathesis (see Figs. 1 and 2).
Although our in vitro observations may not necessarily apply
in vivo, some information may accrue in respect of the role of
oxidants and antioxidants in blood biochemistry and how this
can be modi¢ed to control a bleeding diathesis. As the di¡er-
ential e¡ects of oxidants and antioxidants show, it may be
possible to induce changes in clotting times in respect of either
pathway. Modulation of blood-clotting times may be induced,
for example, by dietary intake of antioxidants such as the
carotenoids, £avonoids, tocopherols (vitamin E) and vitamin
C (L-ascorbic acid). The ‘blood-thinning’ e¡ects of these
agents have been known for some time and may explain our
observations. On the other hand, bleeding diathesis, such as
haemophilia, may also be exacerbated by the intake of anti-
oxidants. Thus, some basic information for new forms of anti-
coagulant therapy based on antioxidants may be derived from
our observations.
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